News - Osiris Therapeutics


Current filters:

Osiris Therapeutics

Popular Filters

Osiris regains worldwide rights to Prochymal and Chondrogen from Sanofi


As a result of the termination of its collaboration with Genzyme, a subsidiary of French drug major Sanofi…

BiotechnologyChondrogenGenzymeImmunologicalsInflammatory diseasesLicensingOsiris TherapeuticsPharmaceuticalProchymalSanofi

Osiris gets second approval for Prochymal, in New Zealand


USA-based Osiris Therapeutics (Nasdaq: OSIR) has received a second approval to market its first-in-class…

Asia-PacificBiotechnologyImmunologicalsOsiris TherapeuticsProchymalRegulation

World's first stem cell drug, Osiris' Prochymal, approved in Canada


USA-based Osiris Therapeutics (Nasdaq: OSIR) has received market authorization from Health Canada to…

BiotechnologyImmunologicalsNorth AmericaOsiris TherapeuticsProchymalRegulation

Sanofi surprises Osiris by pulling out of Prochymal deal


Maryland, USA-based Osiris Therapeutics (Nasdaq: OSIR) has provided an update on the status of the development…

GenzymeImmunologicalsLicensingOsiris TherapeuticsPharmaceuticalProchymalSanofi

Back to top